COMPOSITION FOR USE IN THE PREVENTION AND/OR TREATMENT OF DISEASES MEDIATED BY TLR4, IL1R, COX1/2 AND/OR RBP4 nº EP 22 382 696.7

Innate immunity responses have an essential role in the pathogenesis and progression of multiple rheumatic pathologies, but also other diseases such as COVID19, sepsis, fibrosis, etc. It is widely described how an inflammatory environment also contributes to the onset and development of these pathologies.

Among these inflammatory activators are interleukin (IL-1), toll-like receptor 4 (TLR4), cyclooxygenase enzymes (COX 1/2), and retinol-binding protein 4 (RBP4). IL-1 is a known proinflammatory cytokine. Toll-like receptors (TLRs) are known for their ability to recognize some pathogen-associated molecular patterns (PAMPs). In addition, these receptors are also capable of detecting their own molecules, which arise in a situation of tissue damage (DAMPs). Cyclooxygenase enzymes also play a key role in the development and progression of these responses. Likewise, retinol binding protein 4 is widely described as an adipokine and has been associated with metabolic diseases such as diabetes, obesity, or metabolic syndrome. However, in a chronic basal inflammation, RBP4 also plays an important role.

Therefore, the objective of this research was finding molecules that can block these signals in order to find a treatment for these diseases. We have isolated three active principles from a Brazilian herb that inhibit the inflammatory responses triggered by these receptors (IL1R, TLR4, COX 1-2 and RBP4). Therefore, this new patent (EP22382696.7) offers new tools to control the activation of the innate immune system in several pathological contexts.